Achondroplasia

Aug 13, 2020

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia

Apr 06, 2020

BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe

Dec 16, 2019

BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide

Nov 14, 2019

Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York

Nov 14, 2019

BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

Nov 06, 2019

BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th

Jun 18, 2019

BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

Apr 23, 2019

The Palm Beach Fertility Center Offers a New Screening Test for Over 20 Single Gene Disorders

Nov 01, 2018

BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York

Jun 14, 2018

BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia